PureTech Health plc (LON:PRTC - Get Free Report) shares crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 140.13 ($1.79) and traded as high as GBX 142.20 ($1.82). PureTech Health shares last traded at GBX 138.80 ($1.77), with a volume of 544,139 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reiterated a "buy" rating and issued a GBX 455 ($5.81) price objective on shares of PureTech Health in a research report on Monday, December 16th.
View Our Latest Report on PureTech Health
PureTech Health Price Performance
The firm has a market capitalization of £352.05 million, a PE ratio of -4.81 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The business's 50 day moving average is GBX 138.62 and its two-hundred day moving average is GBX 149.16.
About PureTech Health
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Recommended Stories
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
